Cohort profile: The Canadian observational cohort collaboration

International Journal of Epidemiology

Volumn 40, Issue 1, 2011, Pages 25-32

  Palmer, Alexis K ^a   Klein, Marina B ^b,c   Raboud, Janet ^d,e   Cooper, Curtis ^f,g   Hosein, Sean ^h   Loutfy, Mona ^e,i,j,k   Machouf, Nima ^l   Montaner, Julio ^a,m   Rourke, Sean B ^f,i,n   Smieja, Marek ^f,o   Tsoukas, Christos ^b   Yip, Benita ^a   Milan, David ^a   Hogg, Robert ^a,p  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f ONTARIO HIV TREATMENT NETWORK   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

^h Canadian AIDS Treatment Information Exchange   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j MAPLE LEAF MEDICAL CLINIC   (Canada)

^k WOMEN S COLLEGE HOSPITAL   (Canada)

^l Clinique Medicale l'Actuel   (Canada)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁿ ST MICHAEL'S HOSPITAL   (Canada)

^o MCMASTER UNIVERSITY   (Canada)

^p SIMON FRASER UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COHORT ANALYSIS; DRUG USER; EPIDEMIC; HUMAN IMMUNODEFICIENCY VIRUS; SOCIOECONOMIC STATUS; WOMENS HEALTH;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANADIAN OBSERVATIONAL COHORT COLLABORATION; COHORT ANALYSIS; DRUG USE; HEALTH SERVICE; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; KNOWLEDGE; MALE HOMOSEXUAL; MEDICAL EDUCATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL;

ANTI-HIV AGENTS; CANADA; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; OBSERVATION; RESEARCH DESIGN;

CANADA; UNITED STATES;

EID: 79952047163     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyp393     Document Type: Article

References (30)

1. Public Health Agency of Canada. Summary: Estimates of HIV prevalence and incidence in Canada, 2008. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, 2009. http://www.phac-aspc.gc.ca/aids-sida/publication/survreport/estimat08-eng.php (9 December 2009, date last accessed).
2. Rusch MLA, Alfonso V, Hankins CA, Montaner JSG, O'Shaughnessy M, Hogg RS. Canada. In: Beck J, Mays N, Whiteside AW, Zuniga JM (eds). The HIV Pandemic Local and Global Implications. Oxford: Oxford University Press, 2006, pp. 545-63.
3. Public Health Agency of Canada. Federal Initiative to Address HIV/AIDS in Canada. http://www.phac-aspc.gc.ca/aids-sida/fi-if/index-eng.php (5 August 2009, date last accessed).
4. UN AIDS. 2008 Report on the Global AIDS Epidemic. Annex 2: Country Progress Indicators. http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_ Global_report.asp (5 August 2009, date last accessed).
5. Raboud J, Bayoumi A, Su D, et al. Regional Differences in Rates of Viral Load Testing in Canada. Can J Infecti Dis Med Microbiol 2009;20 (Suppl B): Abstract no. P211.
6. Cooper C, Ding E, Klein M, et al. Time to virologic suppression among HIV-infected individuals on HAART in Canada. Can J Infecti Dis Med Microbiol 2009;20 (Suppl B): Abstract no. P209.
7. Loutfy M, Genebat M, Moore DM, et al. Increased clinical events in HIV-infected patients who achieve full virologic suppression but fail to attain a CD4 count ≥200 cells/mm3 after two years of combination antire-troviral therapy (cART), Proceedings of the 5th IAS Conference on HIV Pathogenesis and Treatment; 19-22 July 2009. Cape Town, South Africa. Abstract MOPEB001.
8. Therapeutic Guidelines Antiretroviral Therapy for HIV-1 infected adults. Developed by the British Columbia Centre for Excellence in HIV/AIDS. Available at: http://www.cfenet.ubc.ca/content.php?id=12. (5 August 2009, date last accessed).
9. Raboud JM, Abdurrahman ZB, Major C et al. Nonfinancial factors associated with decreased plasma viral load testing in Ontario, Canada. J Acquir Immune Defic Syndr 2005;39:327-32.
10. Lima VD, Kretz P, Palepu A et al. Aboriginal status is a prognostic factor for mortality among antiretroviral naive HIV-positive individuals first initiating HAART. AIDS Res Ther 2006;24:3-14.
11. Balfour L, Kowal J, Silverman A et al. A randomized controlled psycho-education intervention trial: Improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART. AIDS Care 2006;18:830-38.
12. Hogg RS, Yip B, Wood E, Craib KJP, O'Shaughnessy MV, Montaner JSG. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-77.
13. Klein MB, Willemot P, Murphy T, Lalonde RG. The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. AIDS 2004; 18:1895-904.
14. Lima VD, Hogg RS, Harrigan PR et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007;21:685-92.
15. Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003;33:365-72.
16. Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005;6:375-78.
17. Boulassel MR, Morales R, Murphy T, Lalonde RG, Klein MB. Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons. J Med Virol 2006;78:1158-63.
18. Cote HC, Magil AB, Harris M. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther 2006;11:79-86.
19. Cooper CL, Mills E, Angel JB. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection. AIDS 2007;21:71-76.
20. Routy JP, Machouf N, Edwardes MD et al. Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal. AIDS 2004;18:2305-12.
21. Loutfy MR, Raboud JM, Walmsley SL et al. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-contain-ing salvage regimens. Antivir Ther 2004;9:595-602.
22. Hogg RS, Bangsberg DR, Lima VD et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006;3:1571-78.
23. Machouf N, Thomas R, Nguyen VK et al. Effects of drug resistance on viral load in patients failing antiretroviral therapy. J Med Virol 2006;78:608-13.
24. Kitahata MM, Gange SJ, Abraham AG et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360:1815-26.
25. Klein MB, Saeed S, Yang H et al. Cohort Profile: The Canadian HIV-Hepatitis C Co-infection Cohort Study (CCC; CTN 222 Study). Int J Epidemiol 2010;39: 1162-69.
26. Keller M, Lu Y, Lalonde RG, Klein MB. Impact of HIV-1 viral subtype on CD4+ T-lymphocytes decline and clinical outcomes in antiretroviral naive patients with free comprehensive health care. AIDS 2009;23: 731-37.
27. ART Cohort Collaboration. http://www.art-cohort-collaboration.org (5 August 2009, date last accessed).
28. The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Part of the International Databases to Evaluate AIDS (IEDEA) RFA. http://statepiaps.jhsph.edu/naaccord (5 August 2009, date last accessed).
29. OHTN Cohort Study. Member of Ontario HIV Treatment Network. http://www.ohtn.on.ca/Pages/Research/OHTN-Cohort-Study.aspx (5 August 2009, date last accessed).
30. Statistics Canada. Income Research Paper Series: Low Income cut-offs. http://www.statcan.gc.ca/pub/75f0002m/2008002/s2-eng.htm (9 December 2009, date last accessed).